SEC Form 4 · accession 0001997584-26-000004
Immunome Inc. · IMNM
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Robert Lechleider
Officer — Chief Medical Officer
Period of report
Jul 2, 2026
Accepted (ET)
Jul 7, 2026 · 5:42 pm EDT
Rule 10b5-1 plan
yes — trade under a plan
Issuer CIK
0001472012
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Jul 2, 2026 | M | 55,000 | $8.73 | A | 70,805 | D | |
| Common StockF2 | Jul 2, 2026 | S | 22,714 | $21.95 | D | 48,091 | D | |
| Common StockF3 | Jul 2, 2026 | S | 16,214 | $22.76 | D | 31,877 | D | |
| Common StockF4 | Jul 2, 2026 | S | 16,072 | $23.44 | D | 15,805 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Employee Stock Option (right to buy)F5 | $8.73 | Jul 2, 2026 | M | 55,000 | D | — | Oct 26, 2033 | Common Stock | 55,000 | 290,000 | D |
Explanation of responses
- F1The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 26, 2026.
- F2The weighted average sale price for the transaction report was $21.95, and the range of prices were between $21.26 and $22.25, inclusive. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided.
- F3The weighted average sale price for the transaction report was $22.76, and the range of prices were between $22.26 and $23.25, inclusive. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided.
- F4The weighted average sale price for the transaction report was $23.44, and the range of prices were between $23.26 and $23.67, inclusive. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided.
- F525% of the shares subject to the option vested on October 16, 2024, and the remaining shares will vest monthly thereafter over three years.